Barbro Linderholm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Barbro Linderholm has a total of 478 co-authors. Here are the top co-authors by number of shared publications:
Jonas Bergh
Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden
7 shared publicationsJ. Bergh
6 shared publicationsBirgitta Lindh
5 shared publications- Janne Lehtiö
Department of Oncology and Pathology, Karolinska Institutet, SciLifeLab, Solna, Sweden.
5 shared publications - Kjell Grankvist
Umeå University 31 Department of Medical Biosciences Umeå, Sweden
5 shared publications - Marie Sundquist
Östra Greda Research Group, Borgholm, Sweden
5 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (11) , 1467-1479
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
- 24 August 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (11) , 1467-1479
Open AccessSustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
- Open Access
- 11 June 2026
- Published by Elsevier in The Breast
- Vol. 88, 104838
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
- 11 June 2026
- Published by Elsevier in The Breast
- Vol. 88, 104838
Open AccessDe-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
- 21 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1093-1105
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
- 21 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1093-1105
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
- Open Access
- 9 January 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Plasma extracellular vesicles reflect response and prognosis in patients with breast cancer undergoing neoadjuvant treatment
Background: Extracellular vesicles (EVs) are emerging as non-invasive biomarkers in cancer, but their role in monitoring the response to neoadjuvant systemic treatment (NST) in patients with breast cancer remains unclear. This study aimed to assess whether EV concentration and surface marker profiles in plasma reflect treatment response and clinical outcome in patients with early-stage breast cancer receiving NST. Methods: Plasma samples were collected from 59 patients with luminal B-like, HER2-positive, or triple-negative breast cancer before and after NST. EVs were isolated by size exclusion chromatography and characterized by nanoparticle tracking analysis, electron microscopy, Western blotting, and MACSPlex surface marker profiling. Paired samples were available for 29 patients, allowing longitudinal analysis. Results: Patients who achieved pathological complete response (pCR) had significantly lower baseline EV concentrations than those with residual disease. Post-treatment EV levels were also lower in patients who remained free from distant metastasis and had improved breast cancer-specific survival. EV surface marker profiling revealed that CD69, CD29, and CD49e were reduced after NST, whereas CD44 was increased. Notably, EpCAM levels increased specifically in non-PCR patients, suggesting persistent tumor-derived EV release, whereas SSEA-4 levels increased only in patients who achieved pCR. Although EV concentrations and markers differed by subtype and outcome, changes in EV levels following NST were not independently predictive of prognosis. Conclusions: These findings support the potential of plasma-derived EVs as dynamic biomarkers of treatment response, and suggest possible prognostic relevance in breast cancer. Validation in larger, independent cohorts is needed to assess their clinical applicability.
- 9 January 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Open AccessPlasma extracellular vesicles reflect response and prognosis in patients with breast cancer undergoing neoadjuvant treatment
Background: Extracellular vesicles (EVs) are emerging as non-invasive biomarkers in cancer, but their role in monitoring the response to neoadjuvant systemic treatment (NST) in patients with breast cancer remains unclear. This study aimed to assess whether EV concentration and surface marker profiles in plasma reflect treatment response and clinical outcome in patients with early-stage breast cancer receiving NST. Methods: Plasma samples were collected from 59 patients with luminal B-like, HER2-positive, or triple-negative breast cancer before and after NST. EVs were isolated by size exclusion chromatography and characterized by nanoparticle tracking analysis, electron microscopy, Western blotting, and MACSPlex surface marker profiling. Paired samples were available for 29 patients, allowing longitudinal analysis. Results: Patients who achieved pathological complete response (pCR) had significantly lower baseline EV concentrations than those with residual disease. Post-treatment EV levels were also lower in patients who remained free from distant metastasis and had improved breast cancer-specific survival. EV surface marker profiling revealed that CD69, CD29, and CD49e were reduced after NST, whereas CD44 was increased. Notably, EpCAM levels increased specifically in non-PCR patients, suggesting persistent tumor-derived EV release, whereas SSEA-4 levels increased only in patients who achieved pCR. Although EV concentrations and markers differed by subtype and outcome, changes in EV levels following NST were not independently predictive of prognosis. Conclusions: These findings support the potential of plasma-derived EVs as dynamic biomarkers of treatment response, and suggest possible prognostic relevance in breast cancer. Validation in larger, independent cohorts is needed to assess their clinical applicability.
- Open Access
- 16 December 2025
- Published by Springer Nature in npj Breast Cancer
- Vol. 11 (1) , 140
Author Correction: Advancing equitable access to innovation in breast cancer
- 16 December 2025
- Published by Springer Nature in npj Breast Cancer
- Vol. 11 (1) , 140
Open AccessAuthor Correction: Advancing equitable access to innovation in breast cancer
- Open Access
- 10 July 2025
- Published by Springer Nature in npj Breast Cancer
- Vol. 11 (1) , 1-10
Advancing equitable access to innovation in breast cancer
This manuscript critically examines the challenges associated with the design and conduct of academic global breast cancer trials outside the influence of pharmaceutical companies, leveraging insights from the Breast International Group (BIG). In the past 4 decades significant declines in breast cancer mortality have occurred, partly related to industry-academic clinical and translational partnerships with long term study follow up. However, in the past decade these partnerships have largely uncoupled. The increasing complexity and non-alignment of trials, funding constraints, regulatory complexity, declining academic freedom, lack of transparency, and lack of affordability of new agents have become key barriers to equitably improving cancer outcomes. Industry research expenditure in the United States is now 5 fold greater than publically funded academic research. To address these challenges, we advocate for patient centred systemic reforms, with trials balancing commercial interests with public health imperatives. These reforms should include equitable research funding models, streamlined international clinical trial regulatory processes, and increased collaboration across diverse stakeholders. Practical solutions to enhance global trial accessibility and efficacy include leveraging digital technologies, artificial intelligence, real world data, decentralizing clinical trial infrastructure, and embedding translational research frameworks across countries.
- 10 July 2025
- Published by Springer Nature in npj Breast Cancer
- Vol. 11 (1) , 1-10
Open AccessAdvancing equitable access to innovation in breast cancer
This manuscript critically examines the challenges associated with the design and conduct of academic global breast cancer trials outside the influence of pharmaceutical companies, leveraging insights from the Breast International Group (BIG). In the past 4 decades significant declines in breast cancer mortality have occurred, partly related to industry-academic clinical and translational partnerships with long term study follow up. However, in the past decade these partnerships have largely uncoupled. The increasing complexity and non-alignment of trials, funding constraints, regulatory complexity, declining academic freedom, lack of transparency, and lack of affordability of new agents have become key barriers to equitably improving cancer outcomes. Industry research expenditure in the United States is now 5 fold greater than publically funded academic research. To address these challenges, we advocate for patient centred systemic reforms, with trials balancing commercial interests with public health imperatives. These reforms should include equitable research funding models, streamlined international clinical trial regulatory processes, and increased collaboration across diverse stakeholders. Practical solutions to enhance global trial accessibility and efficacy include leveraging digital technologies, artificial intelligence, real world data, decentralizing clinical trial infrastructure, and embedding translational research frameworks across countries.
- Open Access
- 17 January 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 133, 102880
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion
- 17 January 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 133, 102880
Open AccessSafety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Journal of Psychosocial Oncology Research and Practice
- Vol. 7 (1)
Convenient but concerning: patients' experiences of metronomic chemotherapy in metastatic breast cancer
Background: Metronomic chemotherapy (MCT) is an available treatment option in patients with metastatic breast cancer. Since patients' perspectives concerning treatment selection may differ from those of the oncologists, increased knowledge on the patient perspective is needed to facilitate shared decision making. The aim was to explore patients' experiences of metronomic chemotherapy with capecitabine and cyclophosphamide (MCT-CX) with focus on the perceived benefits and drawbacks on everyday life. Methods: This is a qualitative descriptive study using individual semistructured interviews for data collection. Ten women in Sweden aged 43–83 years currently or previously treated with MCT were included. Interviews were analyzed using inductive content analysis. Results: In general, participants experienced MCT-CX as a convenient and easily manageable treatment with modest side effects. They emphasized that MCT-CX enabled them to live a life as close to normal as possible and valued doing so despite noncurable cancer. Participants valued the freedom of having a treatment at home. Participants raised concerns regarding the potential weaker effect of MCT-CX compared with other treatments but viewed the treatment as their lifeline that may keep them alive for just a little bit longer. Conclusions and Interpretations: Our results reveal an ambivalence between participants' satisfaction with the minimal intrusion of MCT-CX on everyday life and the fear of taking a potentially weak and insufficient treatment, something that needs to be addressed in future research and in patient–oncologist communication. From the patients' perspective, MCT-CX is as a feasible treatment option.
- 1 January 2025
- Published by Wolters Kluwer Health in Journal of Psychosocial Oncology Research and Practice
- Vol. 7 (1)
Open AccessConvenient but concerning: patients' experiences of metronomic chemotherapy in metastatic breast cancer
Background: Metronomic chemotherapy (MCT) is an available treatment option in patients with metastatic breast cancer. Since patients' perspectives concerning treatment selection may differ from those of the oncologists, increased knowledge on the patient perspective is needed to facilitate shared decision making. The aim was to explore patients' experiences of metronomic chemotherapy with capecitabine and cyclophosphamide (MCT-CX) with focus on the perceived benefits and drawbacks on everyday life. Methods: This is a qualitative descriptive study using individual semistructured interviews for data collection. Ten women in Sweden aged 43–83 years currently or previously treated with MCT were included. Interviews were analyzed using inductive content analysis. Results: In general, participants experienced MCT-CX as a convenient and easily manageable treatment with modest side effects. They emphasized that MCT-CX enabled them to live a life as close to normal as possible and valued doing so despite noncurable cancer. Participants valued the freedom of having a treatment at home. Participants raised concerns regarding the potential weaker effect of MCT-CX compared with other treatments but viewed the treatment as their lifeline that may keep them alive for just a little bit longer. Conclusions and Interpretations: Our results reveal an ambivalence between participants' satisfaction with the minimal intrusion of MCT-CX on everyday life and the fear of taking a potentially weak and insufficient treatment, something that needs to be addressed in future research and in patient–oncologist communication. From the patients' perspective, MCT-CX is as a feasible treatment option.
- Open Access
- 7 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
There is limited knowledge of the biology of breast cancer (BC) brain metastasis (BM). We primarily aimed to determine the mutations in BCBM and to compare the mutational pattern with the matched primary breast cancer (BC). Secondary aims were to determine mutations in each subgroup (Luminal A-/B-like, HER2+ and TNBC) of BCBM, and to determine survival according to specific mutations. We investigated 57 BCBMs, including 46 cases with matched primary tumors (PT) by targeted Next Generation Sequencing (NGS) using the Cancer Hotspot Panel v2 (ThermoFisher Scientific) covering 207 targeted regions in 50 cancer related genes. Subtype according to immunohistochemistry was re-evaluated. NGS results fulfilling sequencing quality criteria were obtained from 52 BM and 41 PT, out of which 37 were matched pairs. Pathogenic mutations were detected in 66% of PTs (27/41), and 62% of BMs (32/52). TP53 mutations were most frequent; 49% (20/41) of PTs and 48% (25/52) in BMs, followed by PIK3CA mutations; 22% (9/42) in PTs and 25% (13/52) in BMs. Mutations in CDH1, EGFR, HRAS, RB1 CDKN2A and PTEN were detected in single pairs or single samples. Mutational pattern was discordant in 24% of matched pairs. We show a discordance of PIK3CA and TP53 mutations of roughly 25% indicating the need to develop methods to assess mutational status in brain metastasis where analysis of cell-free DNA from cerebrospinal fluid (CSF) has shown promising results.
- 7 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Open AccessDiscordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
There is limited knowledge of the biology of breast cancer (BC) brain metastasis (BM). We primarily aimed to determine the mutations in BCBM and to compare the mutational pattern with the matched primary breast cancer (BC). Secondary aims were to determine mutations in each subgroup (Luminal A-/B-like, HER2+ and TNBC) of BCBM, and to determine survival according to specific mutations. We investigated 57 BCBMs, including 46 cases with matched primary tumors (PT) by targeted Next Generation Sequencing (NGS) using the Cancer Hotspot Panel v2 (ThermoFisher Scientific) covering 207 targeted regions in 50 cancer related genes. Subtype according to immunohistochemistry was re-evaluated. NGS results fulfilling sequencing quality criteria were obtained from 52 BM and 41 PT, out of which 37 were matched pairs. Pathogenic mutations were detected in 66% of PTs (27/41), and 62% of BMs (32/52). TP53 mutations were most frequent; 49% (20/41) of PTs and 48% (25/52) in BMs, followed by PIK3CA mutations; 22% (9/42) in PTs and 25% (13/52) in BMs. Mutations in CDH1, EGFR, HRAS, RB1 CDKN2A and PTEN were detected in single pairs or single samples. Mutational pattern was discordant in 24% of matched pairs. We show a discordance of PIK3CA and TP53 mutations of roughly 25% indicating the need to develop methods to assess mutational status in brain metastasis where analysis of cell-free DNA from cerebrospinal fluid (CSF) has shown promising results.
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1341-1348
Breaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to Have
PURPOSE: This study explores the preferences of patients with cancer, family caregivers, and the general public regarding breaking bad news in an Ethiopian oncology setting. METHODS: The study was conducted at Tikur Anbessa (Black Lion) Specialized Hospital. The sample consists of patients with a confirmed cancer diagnosis, their family caregivers, and representatives from the general public with 150 subjects per cohort. The study used a comparative cross-sectional design and multivariable data analysis. RESULTS: The patients would like to be informed, which contradicts the preferences of family caregivers. This creates an ethical dilemma for staff in terms of how much they involve their patients in clinical decision making. The patients also indicate that information should not be withheld from them. By contrast, the general public prefers information about poor life expectancy to be communicated to family only, which may reflect a widespread public perception of cancer as a deadly disease. CONCLUSION: The findings indicate the complexity of communication-related preferences concerning breaking bad news in oncology care in Ethiopia. It requires oncologists to probe patient attitudes before information disclosure to find a balance between involving patients in communication at the same time as keeping a constructive alliance with family caregivers.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1341-1348
Open AccessBreaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to Have
PURPOSE: This study explores the preferences of patients with cancer, family caregivers, and the general public regarding breaking bad news in an Ethiopian oncology setting. METHODS: The study was conducted at Tikur Anbessa (Black Lion) Specialized Hospital. The sample consists of patients with a confirmed cancer diagnosis, their family caregivers, and representatives from the general public with 150 subjects per cohort. The study used a comparative cross-sectional design and multivariable data analysis. RESULTS: The patients would like to be informed, which contradicts the preferences of family caregivers. This creates an ethical dilemma for staff in terms of how much they involve their patients in clinical decision making. The patients also indicate that information should not be withheld from them. By contrast, the general public prefers information about poor life expectancy to be communicated to family only, which may reflect a widespread public perception of cancer as a deadly disease. CONCLUSION: The findings indicate the complexity of communication-related preferences concerning breaking bad news in oncology care in Ethiopia. It requires oncologists to probe patient attitudes before information disclosure to find a balance between involving patients in communication at the same time as keeping a constructive alliance with family caregivers.